Becton Dickinson India

Name

Becton Dickinson India

Legal name

Becton, Dickinson and Company

Website

https://bd.com

Company type

Public

Founded year

1897

Operating status

Operating

Headcount range

5,001–10,000 employees

Ownership category

akta.pro rank

Product category

Medical Devices and Diagnostic Systems

NAICS

Surgical and Medical Instrument Manufacturing (339112), In-Vitro Diagnostic Substance Manufacturing (325413), Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

IVD Reagents, Assay Kits & Consumables (Non-instrument) (HLAHAAAM)

akta.pro secondary industries

Surgical Stapling, Suturing & Hemostasis (Staplers, Clips, Sealants, Tourniquets) (HLAHADAL), Diagnostic & Laboratory Packaging (Specimen Containers, Transport Tubes) (IMALAIAF), Primary Pharmaceutical Packaging (Blister Packs, Bottles, Vials, Ampoules) (IMALAIAA)

Keywords

• Medical devices
• Medication management systems
• Diagnostic instruments
• Vascular access products
• Hypodermic needle manufacturing

Headquarters

HQ city

Gurugram

HQ country

India

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations

Revenue model

1. Medical Devices and Consumables: Sale of medical supplies and devices including syringes, needles, catheters, vascular access products, surgical instruments, and diagnostic consumables. Generates recurring revenue from consumables used in healthcare settings.
2. Medication Management Systems: BD Pyxis medication dispensing technologies and BD Alaris Infusion Systems with AI-powered analytics. Systems typically sold with ongoing consumable revenue.
3. Diagnostic Systems and Reagents: Blood culture systems (BACTEC), molecular diagnostics (BD MAX), microbiology automation (BD Kiestra, BD Phoenix), flow cytometry (FACSLyric), and associated reagents and consumables.
4. Biologic Drug Delivery: Prefilled injectable devices and wearable injectors for GLP-1 and other biologic drugs. Growing segment surpassing $1 billion in annual revenue.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels8 records

Core offering

Becton Dickinson India develops, manufactures, and sells medical devices, instrument systems, and reagents across three segments: BD Medical (medication delivery, vascular access, surgery, urology, and hazardous drug safety), BD Life Sciences (specimen collection, diagnostic systems, clinical microbiology, molecular diagnostics, and lab automation), and BD Interventional (vascular and oncology). The portfolio spans more than 8,299 products including BD Pyxis medication management, BD Alaris infusion systems, BD BACTEC blood culture, BD MAX molecular diagnostics, BD Kiestra lab automation, BD ChloraPrep surgical prep, hypodermic needles and syringes, vascular access devices, and surgical meshes, sold primarily to hospitals, health systems, ambulatory surgery centers, laboratories, and pharmacies.

Product overview

BD (Becton, Dickinson and Company) is a global medical technology company that develops, manufactures, and sells medical devices, instrument systems, and reagents. The company operates across three main segments: BD Medical (medication delivery, vascular access, surgery, urology, acute urology, and hazardous drug safety), BD Life Sciences (specimen collection, diagnostic accuracy, clinical microbiology, molecular diagnostics, and lab automation), and BD Interventional (vascular access management, peripheral intervention, and oncology). The portfolio includes integrated platforms like BD Pyxis Pro for medication management, BD Alaris Infusion System, and BD Incada Connected Care Platform, alongside specialized products such as BD BACTEC blood culture systems, BD Kiestra lab automation, BD FACSLyric flow cytometry, BD ChloraPrep surgical prep, PureWick external catheters, and BD PhaSeal closed-system drug transfer devices. BD serves healthcare institutions, laboratories, and clinicians across acute care, alternate sites, and home healthcare settings worldwide.

Differentiator

Problem solved

Functional benefit

Brands

• BD Alaris: Infusion systems and medication management technology
• BD Pyxis
• BD Vacutainer
• BD BACTEC
• PureWick
• BD ChloraPrep
• BD Libertas
• HemoSphere
• Phasix
• Venovo
• CentroVena One
• Elyra

Products and services

• BD Pyxis Pro Dispensing Solution

Quantifiable outcome

• CentroVena One reduces procedural steps by 30% and insertion time by 50% compared to traditional central line placement
• +6 more outcomes

Named customers3 records

Segments6 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability8 records

Feature8 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• Wellstar Health SystemcoreStrategic or Co-development Partner · 5 May 2026Strategic partnership to deploy AI-powered medication management technology across Wellstar's Georgia-based hospitals and care facilities. Combines BD Pyxis Pro medication dispensing technologies and BD Alaris Infusion Systems powered by BD Incada AI analytics. Provides enterprise-wide medication inventory visibility, real-time insights, and streamlined clinical workflows through EMR interoperability. Wellstar joins BD's Strategic Development Council to shape future medication management innovation.
• Quvara MedicalminorChannel Partner/ Reseller/ Distributor · 15 April 2026Transfer of BD's Swindon, UK production facility to Quvara Medical. Facility continues producing BD products under partnership agreement while Quvara builds independent operations. Transfer of 300+ employees.
• Envetec Sustainable TechnologiesminorStrategic or Co-development Partner · 1 January 2026Closed-loop recycling feasibility study partnership to advance recycling of healthcare plastics, supporting BD's sustainability goals and circular economy initiatives in pharmaceutical packaging.
• Waters CorporationcoreStrategic or Co-development Partner · 1 September 2025Reverse Morris Trust transaction combining BD's Biosciences & Diagnostic Solutions business with Waters Corporation for approximately $17.5 billion (at ~19x EBITDA multiple). Generated $4 billion in cash for BD, deployed toward $2B share buybacks and $2B debt repayment. Transformed BD into a pure-play medical technology company.
• BactiguardcoreOEM/ Whitelabel/ Licensing Partner · 1 January 2025Global licensing partnership for infection-prevention catheter technologies. Bactiguard's noble metal alloy coating technology licensed for use on BD's Foley catheters and other urology products. FDA 510(k) cleared products include Bardex I.C. Foley Catheter with Bactiguard coating shown to lower CAUTI occurrence.
• Edwards Lifesciences (Critical Care Product Group)coreTechnology or Integration · 1 September 2024Acquisition of Edwards Lifesciences' Critical Care product group for advanced hemodynamic monitoring technologies. Enriched BD's portfolio with AI-powered monitoring technologies including ForeSight IQ tissue oximetry sensors and Swan-Ganz pulmonary artery catheters.
• PreAnalytiX GmbH and QIAGENminorStrategic or Co-development Partner · 1 July 2024Strategic alliance to develop standardized urine liquid biopsy solution for non-invasive cell-free DNA analysis. Combines expertise in specimen collection, nucleic acid preservation, and molecular diagnostics.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Becton, Dickinson and Company (Global Parent): BD's global parent entity headquartered in Franklin Lakes, NJ. Operates the same medical device, diagnostics, and medication management portfolio across all geographies; the Indian operations are a regional subset of this parent and share product lines, brands, and management.
• B. Braun: German medical device and pharmaceutical company with overlapping portfolios in IV therapy, syringes, infusion pumps, surgical instruments, and urology. Directly competes with BD in hospital consumables and infusion systems globally, including India.
• Baxter International: Global medical products company with overlapping product lines in IV infusion pumps, IV sets, surgical products, and patient monitoring. Competes directly with BD in medication delivery and surgical solutions across global hospital channels.
• ICU Medical: Specialist in IV infusion systems, medical connectors, and closed-system transfer devices. Direct competitor to BD's Alaris infusion platform and hazardous drug safety portfolio (PhaSeal), competing head-to-head on hospital infusion contracts.
• Smith+Nephew: Global medical technology company with strong positions in advanced wound management, surgical devices, and orthopedics. Directly competes with BD's surgical solutions portfolio and hernia repair products in the surgical suite.
• Teleflex: Specializes in single-use medical devices for critical care and surgical applications including vascular access, anesthesia, and urology. Closely comparable to BD's vascular access and acute care segments with similar hospital-channel distribution.
• Cardinal Health: Major medical supply distributor and medical product manufacturer. Competes with BD both as a distribution channel for hospital products and increasingly through its own manufactured consumables and medical devices portfolio.

Broad incumbents

• Medtronic: Largest diversified medical device company worldwide. Overlaps with BD in vascular access, surgical instruments, patient monitoring, and diabetes. While broader in therapeutic areas, Medtronic competes with BD on procedural efficiency and hospital contracts.
• Abbott Laboratories: Diversified global healthcare company with major diagnostics and medical device segments. Competes with BD's diagnostics franchise (especially post-Waters spin-off) and shares the connected health/patient monitoring opportunity.
• Thermo Fisher Scientific: Largest life sciences tools and diagnostics company globally. Overlaps with BD in clinical diagnostics, microbiology automation, and specimen collection, particularly relevant as BD divests its Biosciences and Diagnostic Solutions business.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/BDandCo
• YouTubeyoutube.com/channel/UCPGmutY43EjP_3ijOugNGnA
• Facebookfacebook.com/BectonDickinsonandCo
• LinkedInlinkedin.com/company/bd1
• Instagraminstagram.com/becton_dickinson

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles19 records

Subsidiaries5 records

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A32 records

Investments13 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Becton Dickinson India